Limits...
18F-MK-9470 PET imaging of the type 1 cannabinoid receptor in prostate carcinoma: a pilot study.

Emonds KM, Koole M, Casteels C, Van den Bergh L, Bormans GM, Claus F, De Wever L, Lerut E, Van Poppel H, Joniau S, Dumez H, Haustermans K, Mortelmans L, Goffin K, Van Laere K, Deroose CM, Mottaghy FM - EJNMMI Res (2013)

Bottom Line: For three patients with proven advanced metastatic disease, two static PET/CTs were performed 1 and 3 h post-injection. 18F-MK-9470 uptake was evaluated in bone lesions of metastatic PCa by comparing SUVmean values of metastases with these of the contralateral bone tissue. 18F-MK-9470 uptake was significantly higher in benign and malignant prostate tissue compared to muscle, but it did not differ between both prostate tissue compartments.Metastases in the axial skeleton could not be detected while some metastases in the appendicular skeleton showed higher 18F-MK-9470 uptake as compared to the uptake in contralateral normal bone. 18F-MK-9470 PET could not detect local PCa or bone metastases in the axial skeleton but was able to visualize metastases in the appendicular skeleton.Based on these pilot observations, it seems unlikely that CB1R PET will play a significant role in the evaluation of PCa.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Nuclear Medicine, University Hospitals Leuven, Leuven 3000, Belgium. fmottaghy@ukaachen.de.

ABSTRACT

Background: Preclinical and histological data show overexpression of the type 1 cannabinoid receptor (CB1R) in prostate carcinoma (PCa). In a prospective study, the feasibility of 18F-MK-9470 positron emission tomography (PET) imaging in patients with primary and metastatic PCa was evaluated.

Methods: Eight patients were included and underwent 18F-MK-9470 PET/CT imaging. For five patients with primary PCa, dynamic PET/CT imaging was performed over three acquisition intervals (0 to 30, 60 to 90 and 120 to 150 min post-injection). In malignant and benign prostate tissue regions, time activity curves of the mean standardized uptake value (SUVmean) were determined as well as the corresponding area under the curve to compare 18F-MK-9470 uptake over time. Muscle uptake of 18F-MK-9470 was used as reference for non-specific binding. Magnetic resonance imaging (MRI) was used as anatomical reference and for delineating intraprostatic tumours. Histological and immunohistochemical (IHC) examination was performed on the whole-mount histopathology sections of four patients who underwent radical prostatectomy to assess the MRI-based tumour versus benign tissue classification. For three patients with proven advanced metastatic disease, two static PET/CTs were performed 1 and 3 h post-injection. 18F-MK-9470 uptake was evaluated in bone lesions of metastatic PCa by comparing SUVmean values of metastases with these of the contralateral bone tissue.

Results: 18F-MK-9470 uptake was significantly higher in benign and malignant prostate tissue compared to muscle, but it did not differ between both prostate tissue compartments. IHC findings of corresponding prostatic histopathological sections indicated weak CB1R expression in locally confined PCa, which was not visualized with 18F-MK-9470 PET. Metastases in the axial skeleton could not be detected while some metastases in the appendicular skeleton showed higher 18F-MK-9470 uptake as compared to the uptake in contralateral normal bone.

Conclusions: 18F-MK-9470 PET could not detect local PCa or bone metastases in the axial skeleton but was able to visualize metastases in the appendicular skeleton. Based on these pilot observations, it seems unlikely that CB1R PET will play a significant role in the evaluation of PCa.

No MeSH data available.


Related in: MedlinePlus

PET/MRI imaging in locally confined PCa. PET/MRI fusion image of the first (A), second (B) and third (C) acquisition time interval in a representative patient (patient 4). The uptake of 18F-MK-9470 in the local tumour is comparable to the uptake in the surrounding healthy prostatic tissue. T, tumour; M, muscle. Data are scaled from 0 to 3 SUV.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3750838&req=5

Figure 3: PET/MRI imaging in locally confined PCa. PET/MRI fusion image of the first (A), second (B) and third (C) acquisition time interval in a representative patient (patient 4). The uptake of 18F-MK-9470 in the local tumour is comparable to the uptake in the surrounding healthy prostatic tissue. T, tumour; M, muscle. Data are scaled from 0 to 3 SUV.

Mentions: The uptake of 18F-MK-9470 over time in tumour and benign prostatic regions compared to the uptake in muscle tissue is demonstrated in Figure 2B. Based on the AUC, no significantly different 18F-MK-9470 uptake was observed between tumoural and benign prostatic regions; nevertheless, the uptake in both prostate compartments was significantly higher than that in the muscle tissue in the first (0 to 30 min, p < 0.05) and last (120 to 150 min, p < 0.05) acquisition time interval. Table 3 presents the mean AUC values of each specific region (PCa, benign prostate, muscle) over time. Figure 3 illustrates the comparable uptake of 18F-MK-9470 in the local tumour as compared with the uptake in the surrounding healthy prostatic tissue.


18F-MK-9470 PET imaging of the type 1 cannabinoid receptor in prostate carcinoma: a pilot study.

Emonds KM, Koole M, Casteels C, Van den Bergh L, Bormans GM, Claus F, De Wever L, Lerut E, Van Poppel H, Joniau S, Dumez H, Haustermans K, Mortelmans L, Goffin K, Van Laere K, Deroose CM, Mottaghy FM - EJNMMI Res (2013)

PET/MRI imaging in locally confined PCa. PET/MRI fusion image of the first (A), second (B) and third (C) acquisition time interval in a representative patient (patient 4). The uptake of 18F-MK-9470 in the local tumour is comparable to the uptake in the surrounding healthy prostatic tissue. T, tumour; M, muscle. Data are scaled from 0 to 3 SUV.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3750838&req=5

Figure 3: PET/MRI imaging in locally confined PCa. PET/MRI fusion image of the first (A), second (B) and third (C) acquisition time interval in a representative patient (patient 4). The uptake of 18F-MK-9470 in the local tumour is comparable to the uptake in the surrounding healthy prostatic tissue. T, tumour; M, muscle. Data are scaled from 0 to 3 SUV.
Mentions: The uptake of 18F-MK-9470 over time in tumour and benign prostatic regions compared to the uptake in muscle tissue is demonstrated in Figure 2B. Based on the AUC, no significantly different 18F-MK-9470 uptake was observed between tumoural and benign prostatic regions; nevertheless, the uptake in both prostate compartments was significantly higher than that in the muscle tissue in the first (0 to 30 min, p < 0.05) and last (120 to 150 min, p < 0.05) acquisition time interval. Table 3 presents the mean AUC values of each specific region (PCa, benign prostate, muscle) over time. Figure 3 illustrates the comparable uptake of 18F-MK-9470 in the local tumour as compared with the uptake in the surrounding healthy prostatic tissue.

Bottom Line: For three patients with proven advanced metastatic disease, two static PET/CTs were performed 1 and 3 h post-injection. 18F-MK-9470 uptake was evaluated in bone lesions of metastatic PCa by comparing SUVmean values of metastases with these of the contralateral bone tissue. 18F-MK-9470 uptake was significantly higher in benign and malignant prostate tissue compared to muscle, but it did not differ between both prostate tissue compartments.Metastases in the axial skeleton could not be detected while some metastases in the appendicular skeleton showed higher 18F-MK-9470 uptake as compared to the uptake in contralateral normal bone. 18F-MK-9470 PET could not detect local PCa or bone metastases in the axial skeleton but was able to visualize metastases in the appendicular skeleton.Based on these pilot observations, it seems unlikely that CB1R PET will play a significant role in the evaluation of PCa.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Nuclear Medicine, University Hospitals Leuven, Leuven 3000, Belgium. fmottaghy@ukaachen.de.

ABSTRACT

Background: Preclinical and histological data show overexpression of the type 1 cannabinoid receptor (CB1R) in prostate carcinoma (PCa). In a prospective study, the feasibility of 18F-MK-9470 positron emission tomography (PET) imaging in patients with primary and metastatic PCa was evaluated.

Methods: Eight patients were included and underwent 18F-MK-9470 PET/CT imaging. For five patients with primary PCa, dynamic PET/CT imaging was performed over three acquisition intervals (0 to 30, 60 to 90 and 120 to 150 min post-injection). In malignant and benign prostate tissue regions, time activity curves of the mean standardized uptake value (SUVmean) were determined as well as the corresponding area under the curve to compare 18F-MK-9470 uptake over time. Muscle uptake of 18F-MK-9470 was used as reference for non-specific binding. Magnetic resonance imaging (MRI) was used as anatomical reference and for delineating intraprostatic tumours. Histological and immunohistochemical (IHC) examination was performed on the whole-mount histopathology sections of four patients who underwent radical prostatectomy to assess the MRI-based tumour versus benign tissue classification. For three patients with proven advanced metastatic disease, two static PET/CTs were performed 1 and 3 h post-injection. 18F-MK-9470 uptake was evaluated in bone lesions of metastatic PCa by comparing SUVmean values of metastases with these of the contralateral bone tissue.

Results: 18F-MK-9470 uptake was significantly higher in benign and malignant prostate tissue compared to muscle, but it did not differ between both prostate tissue compartments. IHC findings of corresponding prostatic histopathological sections indicated weak CB1R expression in locally confined PCa, which was not visualized with 18F-MK-9470 PET. Metastases in the axial skeleton could not be detected while some metastases in the appendicular skeleton showed higher 18F-MK-9470 uptake as compared to the uptake in contralateral normal bone.

Conclusions: 18F-MK-9470 PET could not detect local PCa or bone metastases in the axial skeleton but was able to visualize metastases in the appendicular skeleton. Based on these pilot observations, it seems unlikely that CB1R PET will play a significant role in the evaluation of PCa.

No MeSH data available.


Related in: MedlinePlus